Inhibikase Therapeutics (IKT) Liabilities and Shareholders Equity (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $173.3 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $173.3 million, up 83.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $523.0 million (up 153.77% YoY), and the FY2025 annual result was $181.2 million, up 83.78% from the prior year.
• Liabilities and Shareholders Equity fell to $173.3 million in Q1 2026 per IKT's latest filing, from $181.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $181.2 million in Q4 2025 and troughed at $4.4 million in Q3 2024.
• A 5-year average of $55.8 million and a median of $28.6 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity tumbled 75.52% in 2024, then soared 1718.52% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $24.9 million in 2022, then plunged by 41.83% to $14.5 million in 2023, then jumped by 579.69% to $98.6 million in 2024, then soared by 83.78% to $181.2 million in 2025, then declined by 4.34% to $173.3 million in 2026.
• Business Quant data shows IKT's Liabilities and Shareholders Equity at $173.3 million in Q1 2026, $181.2 million in Q4 2025, and $79.6 million in Q3 2025.